Compile Data Set for Download or QSAR
Report error Found 714 of affinity data for UniProtKB/TrEMBL: P23467
TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50: 0.0100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50: 0.0100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50: 0.0100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50: 0.0100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50: 0.0100nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359101(US10220048, Compound AA11 | US10952992, No. AA11 |...)
Affinity DataIC50: 0.0100nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50: 0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50: 0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50: 0.0800nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50: 0.0800nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359106(US10220048, Compound AA16 | US10952992, No. AA16 |...)
Affinity DataIC50: 0.0800nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359121(US10220048, Compound AA31 | US10952992, No. AA31 |...)
Affinity DataIC50: 0.0800nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50: 0.0900nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50: 0.0900nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50: 0.0900nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50: 0.0900nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50: 0.0900nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359113(US10220048, Compound AA23 | US10952992, No. AA23 |...)
Affinity DataIC50: 0.0900nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50: 0.100nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50: 0.100nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50: 0.100nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359099(US10220048, Compound AA9 | US10952992, No. AA9 | U...)
Affinity DataIC50: 0.100nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359104(US10220048, Compound AA14 | US10952992, No. AA14 |...)
Affinity DataIC50: 0.100nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359118(US10220048, Compound AA28 | US10952992, No. AA28 |...)
Affinity DataIC50: 0.100nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50: 0.140nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50: 0.140nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50: 0.140nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50: 0.140nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50: 0.140nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359117(US10220048, Compound AA27 | US10952992, No. AA27 |...)
Affinity DataIC50: 0.140nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/8/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359091(US10220048, Compound AA75 | US10220048, Compound A...)
Affinity DataIC50: 0.157nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., Design and Synthesis of Potent, No...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase beta(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM359091(US10220048, Compound AA75 | US10220048, Compound A...)
Affinity DataIC50: 0.157nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

Displayed 1 to 50 (of 714 total ) | Next | Last >>
Jump to: